Clinical Efficacy of Metoprolol Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure

A total of 120 chronic heart failure patients admitted to our hospital from June 2020 to October 2022 were randomly separated into observation group (receiving sacubitril/valsartan in combination with metoprolol therapy) and control group (receiving metoprolol treatment), with 60 cases in each group. The cardiac function indexes, myocardial injury indexes, inflammatory cytokines, oxidative stress index, occurrence of adverse reactions, NT-proB-type natriuretic peptide and treatment effects in both groups were assessed. After treatment, left ventricular end-diastolic dimension and left ventricular end-systolic diameter were lower, while left ventricular ejection fraction and stroke volume were higher in the observation group than the control group. Lactate dehydrogenase, creatine kinase-MB, cardiac troponin I, tumor necrosis factor-a, interleukin-6, C-reactive protein, malondialdehyde, NT-proB-type natriuretic peptide levels were declined, while total antioxidant capacity was elevated in the observation group in contrast to the control group. The observation group has lower occurrence rates of adverse reactions and higher total effective rates. To sum up, in the therapy of chronic heart failure, the use of sacubitril/valsartan combined with metoprolol can help to promote the cardiac function of patients, reduce the levels of inflammatory factors and clinical symptoms, and the therapeutic effect is good.